



# *Alpa Laboratories Ltd.*

**33/2, Pigdambar A.B. Road - 453 446 Distt. Indore - (M.P.) India**

Phone No. : +91 731-429 4567 Fax No. : +91 730-429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

13<sup>th</sup> August, 2024

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001

To,  
Listing Department,  
National Stock Exchange of India Limited.  
Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051

Subject: Unaudited Financial Results for the year ended 30<sup>th</sup> June, 2024

Reference: Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir

Please refer to our intimation submitted on 3<sup>rd</sup> August, 2024

Pursuant to the applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the following.

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter ended on 30<sup>th</sup> June, 2024 with Limited Review Report from the Statutory Auditor of the Company.
2. Approval of the Notice of 36<sup>th</sup> Annual General Meeting of the Company.

The Meeting commenced at 4:00 pm and concluded at 7:15 pm.

Conclusion

You are requested to take the same on records pursuant to Regulations 30 of SEBI LODR, 2015.

For ALPA LABORATORIES LIMITED

*Mahendra Singh Chawla*  
Mahendra Singh Chawla  
Director



# ALPA LABORATORIES LIMITED

Financial Results for Quarter ended 30th June 2024

33/2 PIGDAMBER, A.B. ROAD,  
RAU INDORE (M.P.) 453446  
(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone				
Particulars	Standalone Results			
	Quarter Ended			Year Ended
	Jun-24	Mar-24	Jun-23	Mar-24
	Unaudited	Audited	Unaudited	Audited
<b>1. Income</b>				
a) Revenue from operations	2,144.37	2,360.66	2,542.96	10,873.90
b) Other Income	516.02	394.95	443.92	1,487.39
<b>Total income from operations</b>	<b>2,660.38</b>	<b>2,755.61</b>	<b>2,986.87</b>	<b>12,361.29</b>
<b>2. Expenses</b>				
a) Cost of materials consumed	1,421.90	929.19	1,716.10	6,287.91
b) Purchases of stock-in-trade	19.12	232.88	116.93	579.75
c) Changes in inventories of finished products, work in progress and stock in trade	(66.71)	(107.86)	197.16	(64.12)
d) Employee benefit expenses	331.10	386.68	297.01	1,325.70
e) Finance costs	5.34	30.39	1.70	38.93
f) Depreciation and amortization expense	54.28	52.47	27.55	195.49
g) Other expenses				
Manufacturing & Operating	128.36	190.49	142.69	656.87
Others	256.37	377.59	187.91	1,273.32
<b>Total expenses</b>	<b>2,149.76</b>	<b>2,091.83</b>	<b>2,687.06</b>	<b>10,293.85</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>510.63</b>	<b>663.78</b>	<b>299.82</b>	<b>2,067.44</b>
<b>4. Exceptional Items</b>	(1.82)	(1.78)	(2.84)	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>512.45</b>	<b>665.56</b>	<b>302.66</b>	<b>2,067.44</b>
<b>6. Tax (Expenses)/ Benefit</b>				
Current tax	-	(300.00)	-	(300.00)
Deffered Tax	-	(11.30)	-	(11.30)
Tax Related to Earlier Years	-	0.37	-	(78.37)
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>512.45</b>	<b>354.63</b>	<b>302.66</b>	<b>1,677.77</b>
<b>8. Other Comprehensive Income</b>				
(i) (a) Items that will not be reclassified to profit or loss	-	3.58	-	8.16
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	-	<b>3.58</b>	-	<b>8.16</b>
<b>9. Total comprehensive income for the period</b>	<b>512.45</b>	<b>358.21</b>	<b>302.66</b>	<b>1,685.93</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity (excluding revaluation reserve)</b>				<b>14,093.20</b>
<b>12. Debiture Redemption Reserve</b>				
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.44</b>	<b>1.70</b>	<b>1.44</b>	<b>8.01</b>

**Notes -**

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- Other Income for the quarter includes unrealized profit occurred on account of increase in fair market value of the investments.

Place: Indore  
Date: August 13, 2024

By order of the board  
For Alpa Laboratories Limited

*Mahendra*  
Mahendra Singh Chawla  
Whole-Time Director



# C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.  
S. C. PADLIYA M. Com., F. C. A.  
VIPUL PADLIYA B. Com., F. C. A.




H.O. : 90, Dawa Bazar, 2nd Floor, 13-14  
RNT Marg, Indore - 452 001 (INDIA)  
Office : +91 731 2704343  
B.O. : 101, Pragati Apartment, Opp. Krashi  
Mandi, Pratapnagar (Raj.)-312605  
Tel. : +1478-22624  
Official webpage : www.chpadliya.com

## Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review report to the Board of Directors of **ALPA LABORATORIES LIMITED,**

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **ALPA LABORATORIES LIMITED** ("the Company") for the quarter ended **30<sup>th</sup> June, 2024**, and year to date results for the period **1<sup>st</sup> April, 2024 to 30<sup>th</sup> June, 2024**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)(Listing Regulations) including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of  
**C.H. PADLIYA & Co.**  
Chartered Accountants  
Firm registration no.003151C

  
**S.C. PADLIYA**  
Partner  
Membership no.071666  
UDIN: 24017666BKWCWZV5508



Date: This 10<sup>th</sup> Day of August, 2024  
Place: Indore

# ALPA LABORATORIES LIMITED

Financial Results for Quarter ended 30th June 2024

33/2 PIGDAMBER, A.B. ROAD,  
RAU INDORE (M.P.) 453446  
(Rs. in lacs except EPS)

Particulars	Consolidated Results			
	Quarter Ended			Year Ended
	Jun-24	Mar-24	Jun-23	Mar-24
	Unaudited	Audited	Unaudited	Audited
<b>1. Income</b>				
a) Revenue from operations	2,144.37	2,360.66	2,144.37	10,873.90
b) Other Income	516.02	396.53	516.02	1,488.97
<b>Total income from operations</b>	<b>2,660.38</b>	<b>2,757.19</b>	<b>2,660.38</b>	<b>12,362.87</b>
<b>2. Expenses</b>				
a) Cost of materials consumed	1,421.90	929.19	1,446.90	6,287.91
b) Purchases of stock-in-trade	19.12	232.88	19.12	579.75
c) Changes in inventories of finished products, work in progress and stock in trade	(66.71)	(107.86)	(66.71)	(64.12)
d) Employee benefit expenses	332.15	387.33	331.10	1,329.05
e) Finance costs	5.17	29.44	5.34	35.92
f) Depreciation and amortization expense	54.28	52.47	54.28	195.49
g) Other expenses				
Manufacturing & Operating	128.36	190.49	128.36	656.87
Others	256.49	377.91	180.74	1,273.80
<b>Total expenses</b>	<b>2,150.76</b>	<b>2,091.85</b>	<b>2,099.12</b>	<b>10,294.67</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>509.62</b>	<b>665.34</b>	<b>561.26</b>	<b>2,068.20</b>
<b>4. Exceptional Items</b>				
		(1.78)	(1.82)	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>509.62</b>	<b>667.12</b>	<b>563.08</b>	<b>2,068.20</b>
<b>6. Tax (Expenses)/ Benefit</b>				
Current tax	-	(300.00)	-	(300.00)
Deferred Tax	-	(11.30)	-	(11.30)
Tax Related to Earlier Years	-	(0.51)	-	(79.25)
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>509.62</b>	<b>355.31</b>	<b>563.08</b>	<b>1,677.65</b>
<b>8. Other Comprehensive Income</b>				
(i) (a) Items that will not be reclassified to profit or loss	(0.26)	3.58	-	8.16
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>(0.26)</b>	<b>3.58</b>	<b>-</b>	<b>8.16</b>
<b>9. Total comprehensive income for the period</b>	<b>509.36</b>	<b>358.89</b>	<b>563.08</b>	<b>1,685.81</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity (excluding revaluation reserve)</b>				<b>13,086.90</b>
<b>12. Debenture Redemption Reserve</b>				
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.42</b>	<b>1.71</b>	<b>2.68</b>	<b>8.01</b>

## Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards ) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- Other Income for the quarter includes unrealized profit occurred on account of increase in fair market value of the investments.

Place: Indore  
Date: August 13, 2024

By order of the board  
For Alpa Laboratories Limited

*Mahendra*

Mahendra Singh Chawla  
Whole-Time Director



# C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14  
RNT Marg, Indore - 452 001 (INDIA)

Office : +91 731 2704343

B.O. : 101, Pragati Appartment, Opp. Krashi  
Mandi, Pratapnagar (Raj.)-312605

Tel. : +1478-22624

Official webpage : www.chpadliya.com

## Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to Regulations 33 of the SEBI (LISTING Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of **ALPA LABORATORIES LIMITED**,

1. We have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** ('the Holding Company') and its subsidiary ('the Holding company and its subsidiary together referred as 'the Group') for the quarter ended 30<sup>th</sup> June, 2024 and the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> June, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations"), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles accepted in India is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial information performed by the independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations (As amended), to the extent applicable.

4. The Statement includes the results of the following entities:

1) Subsidiary:

A. Norfolk Mercantile Private Limited



# C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14  
RNT Marg, Indore - 452 001 (INDIA)  
Office : +91 731 2704343  
B.O. : 101, Pragati Appartment, Opp. Krashi  
Mandi, Pratapnagar (Raj.)-312605  
Tel. : +1478-22624  
Official webpage : www.chpadliya.com

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes interim financial information of subsidiary which have been reviewed by us, whose interim financial information reflect total revenues of INR Nil lakhs and INR Nil lakhs, total net loss of INR 1.01 lakhs and INR 1.01 lakhs and total comprehensive loss of INR 3.09 lakhs and INR 3.09 lakhs for the quarter ended 30<sup>th</sup> June, 2024 and for the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> June, 2024, respectively as considered in the Statement. These interim financial results have been reviewed by us and our conclusion in so far as it relates to the amounts and disclosure included of the subsidiary is based on our review and the procedures performed by us as stated in paragraph 3 above.

For & on behalf of

**C.H. PADLIYA & CO.**

Chartered Accountants

Firm registration no.003151C

**S.C. PADLIYA**

Partner

Membership No. 071666

UDIN: 24071666BKCWZ1820



Date: This 13<sup>th</sup> Day of August, 2024

Place: Indore